Recro Pharma (REPH) Tops Q4 EPS by 23c

Recro Pharma (NASDAQ: REPH) reported Q4 EPS of ($0.45), $0.23 better than the analyst estimate of ($0.68).

For earnings history and earnings-related data on Recro Pharma (REPH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c